Ratings BioCardia, Inc.

Equities

BCDA

US09060U5074

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-15 pm EDT			5-day change	1st Jan Change
0.3999 ^USD	+0.98%		+1.50%	-39.79%

May. 14	Transcript : BioCardia, Inc., Q1 2024 Earnings Call, May 14, 2024
May. 01	BioCardia, Inc. Announces the Primary Endpoint Results of the Open Label Roll-In Cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial	CI

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The opinion of analysts covering the stock has improved over the past four months.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
BIOCARDIA, INC.	-39.79%	10.74M	-
VERTEX PHARMACEUTICALS INCORPORATED	+7.52%	113B	B+
REGENERON PHARMACEUTICALS, INC.	+11.38%	106B	B+
BIONTECH SE	-12.64%	22.22B	B+
ARGENX SE	+0.44%	22.27B	B
GENMAB A/S	-4.18%	19.43B	A-
WUXI APPTEC CO., LTD.	-37.85%	17.87B	A-
BEIGENE, LTD.	-8.58%	17.24B	B
SAREPTA THERAPEUTICS, INC.	+37.41%	12.52B	C+
LEGEND BIOTECH CORPORATION	-23.95%	8.34B	D

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes